Development of a vaccine for *Plasmodium vivax*, a relapsing malaria parasite, lags behind that for *P. falciparum*. This study used the *P. cynomolgi*-rhesus macaque model to test a single-shot, high-dose live sporozoite vaccination approach. The natural relapsing phenotype of the parasite was leveraged to self-boost the immune response. Results showed sterile protection in 75% of animals with limited blood-stage exposure, suggesting that controlled blood-stage exposure might enhance protection. This proof-of-concept study indicates a potential new direction for *P. vivax* vaccine development.

Erica M. Pasini, Annemarie Voorberg van der Wel, Nicole Heijmans, Onny Klop, Anne-Marie Zeeman, Herman Oostermeijer, Ivonne Neurdenburg, Roberto Rodríguez García, Nicole Onur van der Werff, Sam O. Hofman, Frank A. W. Verreck, Edmond J. Remarque, Bart W. Faber, Clemens H. M. Kocken